The effects of thrombopoietin (TPO; c-mpl ligand), FLT3/FLK-2 ligand (FL), and interleukin-6 (IL-6) on the survival of murine hematopoietic long-term reconstituting cells (LTRC) were studied by using lineage-negative, Sca-1–positive, c-kit–positive (LinSca-1+c-kit+) marrow cells from 5-fluorouracil–treated mice. We tested the ability of these cytokines to maintain the viability of LTRC by transplanting the cultured cells to lethally irradiated Ly-5 congenic mice together with compromised marrow cells. As a single agent, only TPO could maintain the LTRC. Neither IL-6 nor FL was effective by itself, but they acted synergistically to maintain the LTRC. We examined whether the maintenance of LTRC by these cytokines was due to the survival of stem cells or was the result of active cell divisions and self-renewal. To monitor cell division, we used membrane dye PKH26. Enriched cells were stained with PKH26 on day 0 and incubated in suspension culture with TPO or with IL-6 and FL for 7 days. On day 7, PKH26low and PKH26high cells were prepared by sorting and their in vivo reconstituting abilities were tested by transplantation into lethally irradiated Ly-5 congenic mice together with compromised marrow cells. PKH26high populations cultured with both TPO alone and the combination of IL-6 and FL showed greater reconstitution activity than that of PKH26low populations. These data indicate that TPO alone and the combination of IL-6 and FL can support the survival of stem cells without stimulating their active cell proliferation.

PROLIFERATION OF primitive hematopoietic progenitors is regulated by a number of cytokines. Based primarily on serial observations of the development of murine and human blast cell colonies, a model of cytokine interactions regulating the proliferation kinetics of primitive progenitors has been proposed.1 In this model, the cytokines are classified into three functional groups.1 Interleukin-3 (IL-3),2IL-4,3 and granulocyte-macrophage colony-stimulating factor (GM-CSF)4,5 form the first group of cytokines that individually can support proliferation of multipotential progenitors after they exit from the cell-cycle dormant state (G0period). A group of IL-6,6 IL-11,7,8IL-12,9 granulocyte colony-stimulating factor (G-CSF),10 and leukemia-inhibitory factor (LIF)11,12 forms the second group. A group consisting of steel factor (SF; c-kit ligand)13,14 and FLT3/FLK-2 ligand (FL)15 forms the third group. Both SF and FL are ligands for receptors with tyrosine kinase activity and they interact with the cytokines in the first and second groups.13-15 

Cytokines are also capable of supporting the survival of primitive progenitors. In the murine system, IL-1α,16IL-3,17-20 IL-4,18 G-CSF,18SF,19-21 and FL22 were shown to support the survival of progenitors including colony-forming units-spleen (CFU-S). IL-3,17-19 IL-4,18 and SF19,23-25were reported also to support the survival in culture of long-term reconstituting cells (LTRC). In the human system, IL-3,12,26 GM-CSF,12 SF,26 and FL27 support the survival of colony-forming cells. Leary et al12 in our laboratory observed that cell cycle dormant progenitors in the CD34+HLA-DR human marrow fraction require either IL-3 or GM-CSF for survival in culture. Brandt et al26 reported that IL-3 or SF supports the survival of human colony-forming cells by testing CD34+HLA-DRc-kit+ bone marrow cells. Using lineage-negative (Lin) CD34++CD38 light-density fetal liver cells, Muench et al27 demonstrated that FL supports the survival of human colony-forming cells.

Despite their similarity, there appears to be some differences in the effects of SF and FL on primitive hematopoietic progenitors.15,28,29 Earlier, we noted that blast-like cells persist longer in FL-containing cultures than in SF-containing cultures.15 More recently, we reported that a combination of FL and IL-11 supports maintenance of the in vivo reconstituting ability of cultured cells longer than the combination of SF and IL-11.28 Petzer et al29 reported that FL alone stimulated a net increase in human long-term culture-initiating cells (LTC-IC), but SF did not.

Recently, thrombopoietin (TPO) was found to possess positive effects on primitive hematopoietic progenitors.30-32 TPO was originally identified as a lineage-specific regulator of megakaryocytopoiesis and thrombopoiesis.33-44 TPO acts through a specific receptor termed c-mpl, which has been detected in not only megakaryocytes and plateletes, but also in cell populations containing stem cells and progenitors.45-49 As mentioned above, Ku et al30 and Kobayashi et al31 in our laboratory and Sitnicka et al32observed that TPO can synergize with SF and/or IL-3 in support of the formation of murine and human multilineage colonies. TPO30 can trigger the cell division of dormant (G0) multipotential progenitors in a manner similar to that previously reported for the second group of cytokines such as IL-6,6 IL-11,7,8 IL-12,9G-CSF,10 and LIF.11 Injection of TPO accelerated erythroid recovery of myelosuppressed mice50,51and, in combination with G-CSF, neutrophil recovery.52Megakaryocyte, erythroid, and myeloid progenitors were reduced in the TPO- or c-mpl–deficient mice.53,54 Administration of TPO to the TPO-deficient mice significantly increased the number of myeloid, erythroid, and mixed progenitors.54 TPO increased production of human LTC-IC in suspension culture.29Together, these observations indicate that TPO may be a regulator of the proliferation of multipotential progenitors.

In this report, we present studies of the ability of TPO to maintain the survival of murine LTRC. Comparison was made with FL and IL-6. As a single agent, TPO appears to be more potent than FL or IL-6 in the maintenance of stem cell activities. In contrast, synergism between IL-6 and FL supported the survival of LTRC. These results are in agreement with the observations in the gene knock-out mice and indicate that TPO has a physiological role in the maintenance of stem cell activity. TPO may be an important factor for in vitro manipulation of hematopoietic stem cells.

Cytokines.

Purified recombinant human TPO was prepared by the Cytokine Production Group of Kirin Brewery (Takasaki, Japan).38,39 Recombinant human FL was produced in yeast and purified as described previously.55 Purified recombinant human IL-6 was a gift from M. Naruto (Toray Industries, Kamakura, Japan). Purified recombinant murine SF was obtained from Immunex (Seattle, WA). Purified recombinant murine IL-3 was purchased from R&D Systems (Minneapolis, MN). Purified recombinant human erythropoietin (EPO) was a gift from F.-K. Lin (Amgen, Thousand Oaks, CA). Unless otherwise specified, the concentration of cytokines used were as follows: 100 ng/mL TPO, 100 ng/mL FL, 100 ng/mL IL-6, 100 ng/mL SF, 10 ng/mL IL-3, and 2 U/mL EPO.

Monoclonal antibodies (MoAbs).

Hybridoma D7 (anti-Ly-6A/E [anti-Sca-1] rat IgG2a) was a gift from P. Kincade (Oklahoma Medical Research Foundation, Oklahoma City, OK). MoAb ACK4 (anti-c-kit; rat IgG2a) was provided by S.I. Nishikawa (Kyoto University, Kyoto, Japan). Hybridoma RB6-8C5 (antimouse granulocytes; rat IgG2b) was provided by R.L. Coffman (DNAX, Palo Alto, CA). MoAb TER119 (anti-erythrocytes; rat IgG2b) was a gift from T. Kina (Kyoto University). Hybridomas 14.8 (anti-B220; rat IgG2b), M1/70.15.11.5 (anti-macrophages; rat IgG2b), GK1.5 (anti-CD4; rat IgG2b), and 53-6.72 (anti-CD8; rat IgG2a) were purchased from American Type Culture Collection (Rockville, MD). 53-2.1 (biotin-conjugated anti–Thy-1.2; rat IgG2a), RA3-6B2 (biotin-conjugated anti-CD45R/B220; rat IgG2a), RB6-8C5 (biotin-conjugated anti–Gr-1; rat IgG2b), and M1/70 (biotin-conjugated anti–Mac-1; rat IgG2b) were purchased from Pharmingen (San Diego, CA). A20-1.7 (fluorescein isothiocyanate [FITC]-conjugated anti–Ly-5.1; mouse IgG1) was provided by H. Fleming (Emory University, Atlanta, GA).

Cell preparations.

Cells from 10- to 16-week-old female C57Bl/6 mice (Charles River Laboratories, Raleigh, NC) were used in suspension and clonal cultures, and cells from 10- to 16-week-old C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) that are congenic for Ly-5 allotypes were used in transplantation experiments. 5-Fluorouracil (5-FU; Adria Laboratories, Columbus, OH) was administered intravenously through the tail vein at 150 mg/kg body weight, and bone marrow cells were harvested 2 days later. Cells prepared from pooled femurs and tibiae were washed twice and then subjected to density gradient separation by using Nycodenz (Accurate Chemical and Scientific Corp, Westbury, NY). Cells with densities ranging from 1.063 to 1.077 g/mL were collected.56 Cells reacting to a cocktail of lineage-specific rat MoAbs (RB6-8C5, 14.8, M1/70.15.11.5, GK1.5, TER119, and 53-6.72) were removed twice by using immunomagnetic beads (Dynabeads M-450 coupled to sheep antirat IgG; DYNAL, Great Neck, NY). The resulting Lin cells were treated with normal rat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) at 20 μg/106 cells to prevent nonspecific binding of MoAbs to Fc receptors and then stained with FITC-conjugated rat MoAb D7 (anti–Sca-157) and biotin-conjugated rat MoAb ACK4 (anti–c-kit58). The cells were washed twice before staining with streptavidin-conjugated R-phycoerythrin (PE) (Jackson ImmunoResearch Laboratories). In the experiments using PKH26, streptavidin-conjugated allophycocyanin (APC; Caltag Laboratories, San Francisco, CA) was used instead of PE, because the emission wave length of PKH26 is similar to that of PE. Both FITC-conjugated rat IgG2a and biotin-labeled rat IgG2a (Caltag Laboratories) were used as isotype controls. Sca-1+c-kit+ cells were collected by sorting on FACS Vantage (Becton Dickinson Immunocytometry Systems, San Jose, CA).

Clonal cell culture.

Methylcellulose cell culture was performed in 35-mm suspension culture dishes (Falcon, Lincoln Park, NJ). One milliliter of culture contained 100 LinSca-1+c-kit+ cells, α-medium (ICN, Irvine, CA), 1.2% 1,500-cp methylcellulose (Shinetsu Chemical, Tokyo, Japan), 30% (vol/vol) fetal calf serum (Intergen, Purchase, NY), 1% deionized fraction V bovine serum albumin (Sigma Chemical, St Louis, MO), 1 × 10−4 mol/L 2-mercaptoethanol (Sigma), and cytokine(s). Dishes were incubated at 37°C in a humidified atmosphere flashed with 5% CO2. Colony types were determined on day 14 by in situ observation on an inverted microscope according to the criteria described previously.59 Megakaryocyte colonies were scored when the colony contained 4 or more megakaryocytes. Abbreviations for colony types are as follows: GM, granulocyte/macrophage colonies; GEM, granulocyte/erythrocyte/macrophage colonies; GMM, granulocyte/macrophage/megakaryocyte colonies; GEMM, granulocyte/erythrocyte/macrophage/megakaryocyte colonies59; and Meg, megakaryocyte colonies.

Survival of progenitors and reconstituting cells in suspension culture.

One thousand LinSca-1+c-kit+cells were incubated in each well of 24-well plate (Falcon) in suspension culture. The culture medium consisted of α-medium, 20% (vol/vol) fetal calf serum, 1% deionized bovine serum albumin, 1 × 10−4 mol/L 2-mercaptoethanol, and cytokine(s). On day 7 of incubation, aliquots of cells were analyzed for progenitors in clonal cell culture and for the in vivo reconstituting cells. Clonal cell culture was performed as described above. Colonies were scored on day 8 of incubation by in situ observation of the plates on an inverted microscope.59 

In vivo reconstitution experiments.

Ten- to 12-week-old female C57Bl/6-Ly-5.2 mice were administered with a single 850-cGy dose of total body irradiation via a 4 × 106 V linear accelerator. After irradiation, 200 freshly sorted LinSca-1+c-kit+ cells of male C57Bl/6-Ly-5.1 mice were injected into the tail vein of the recipients together with 4 × 105 compromised marrow cells of female C57Bl/6-Ly-5.2 mice. Compromised marrow cells had been subjected to two previous rounds of transplantation and regeneration in female mice.60 Cells cultured in suspension were also tested for reconstituting capabilities after 7 days of incubation with a single cytokine or combinations of cytokines. Fractions equivalent to one fifth of a day-7 culture that had been initiated with 1,000 LinSca-1+c-kit+ cells were injected into female C57Bl/6-Ly-5.2 mice together with compromised marrow cells. Peripheral blood was obtained from the retro-orbital venous plexus using heparin-coated micropipettes (Drummond Scientific Co, Broomall, PA) 2 and 5 months after transplantation. Red blood cells were lyzed by 0.15 mol/L NH4Cl. The samples were then used for flow cytometric analysis of donor-derived cells by staining with FITC-conjugated anti–Ly-5.1 (A20-1.7). Donor cells in T-cell, B-cell, granulocyte, and monocyte/macrophage lineages at 5 months posttransplantation were analyzed by staining with biotin-conjugated anti–Thy-1.2, biotin-conjugated anti-CD45R/B220, biotin-conjugated anti–Gr-1, and biotin-conjugated anti–Mac-1. For indirect staining of cells with biotin-conjugated antibodies, cells were first incubated with biotin-conjugated antibodies, followed by staining with streptavidin-conjugated PE.

PKH26 experiments.

LinSca-1+c-kit+ cells of male C57Bl/6-Ly-5.1 mice were stained with PKH26 (Sigma ImmunoChemicals, St Louis, MO) according to the manufacturer's instruction. Briefly, 1 × 105 cells were suspended in 1 mL of diluent (Sigma ImmunoChemicals) and immediately transferred into a polypropylene tube containing 1 mL of 4 × 10−7 mol/L PKH26 in diluent. After incubation for 5 minutes at room temperature, the staining reaction was stopped by adding 2 mL of fetal calf serum. One minute later, the total volume was brought up to 8 mL with α-medium supplemented with 10% fetal calf serum, and the cells were washed three times by using the serum-containing medium. After the third wash, cells were incubated with TPO alone or the combination of IL-6 and FL in a 75-cm2 flask (Corning Coster Co, Cambridge, MA) in 100 mL for 7 days. After washing and staining with 1 μg/mL of propidium iodine (PI), the cells were then analyzed for PKH26 fluorescense on FACS Vantage. Dead (PI-positive) cells were excluded from the sort gate. The viable cells were separated into PKH26low and PKH26high populations by sorting and their reconstituting abilities were tested by transplanting the sorted cells into lethally irradiated Ly-5 congenic mice together with 4 × 105compromised marrow cells. Flow cytometric analyses of the donor-derived cells were performed as described above at 5 months after transplantation. For indirect staining of cells with biotin-conjugated antibodies, cells were first incubated with biotin-conjugated antibodies, followed by staining with streptavidin-conjugated APC instead of PE, because the emission wave length of PE is similar to that of PKH26.

Effects of cytokines on colony formation.

Colony formation from LinSca-1+c-kit+ cells of 5-FU–treated mice is presented in Table 1. As a single agent, FL, IL-6, and TPO in either 100 or 1,000 ng/mL concentrations failed to support significant colony formation. However, IL-6 in synergy with FL supported formation of a number of colonies. Colony types could not be determined in situ, because most colonies supported by the combination of IL-6 and FL contained a number of immature cells.15 Cultures containing a combination of TPO and FL yielded only few Meg colonies, indicating that TPO does not synergize with FL. LinSca-1+c-kit+ cells exhibited about 45% colony-forming efficiency when cultured in cytokine cocktails, SF, IL-3, IL-6, FL, TPO, and EPO.

Table 1.

In Vitro Colony Formation

Cytokines No. of Colonies
GMGEMM GMM GEM Meg Total
None  0   0  0  0  
TPO  
   100 ng/mL  0  0  0  0 ± 1  0 ± 1  
 1,000 ng/mL  0  0  0  0 ± 1  0 ± 1  
FL  
   100 ng/mL 0  0  0  0  0  0  
 1,000 ng/mL  0  0  0  0  0  
IL-6  
   100 ng/mL 0  0  0  0  0  0  
 1,000 ng/mL  0  0  0  0  0  
TPO, FL  0  0  0  1 ± 1  1 ± 1  
IL-6, FL      10 ± 2-150 
Cocktail-151 24 ± 4 13 ± 2  2 ± 1  0 ± 1  5 ± 2 44 ± 8 
Cytokines No. of Colonies
GMGEMM GMM GEM Meg Total
None  0   0  0  0  
TPO  
   100 ng/mL  0  0  0  0 ± 1  0 ± 1  
 1,000 ng/mL  0  0  0  0 ± 1  0 ± 1  
FL  
   100 ng/mL 0  0  0  0  0  0  
 1,000 ng/mL  0  0  0  0  0  
IL-6  
   100 ng/mL 0  0  0  0  0  0  
 1,000 ng/mL  0  0  0  0  0  
TPO, FL  0  0  0  1 ± 1  1 ± 1  
IL-6, FL      10 ± 2-150 
Cocktail-151 24 ± 4 13 ± 2  2 ± 1  0 ± 1  5 ± 2 44 ± 8 

One hundred LinSca-1+c-kit+cells prepared from the marrow of 5-FU–treated mice were plated per dish in the presence of designated cytokine(s). Colonies were scored on day 14 of culture. Data represent the mean and standard deviation of values obtained from quadruplicate dishes.

F0-150

In situ identification of colony types was not possible because of the persistence of blast-like cells.

F0-151

SF, IL-3, IL-6, FL, TPO, and EPO.

Effects of cytokines on maintenance of cells and progenitors.

We next studied the effects of cytokines on the maintenance of cells and colony-forming cells in 7-day suspension culture. The results shown in Table 2 are representative of three experiments. No viable cells were present after 7 days of incubation in medium alone. TPO was the most effective single agent to maintain the survival of progenitors, including CFU-GEMM and CFU-Meg, whereas IL-6 showed minimal activity and FL failed to support the survival of progenitors. The maintenance of progenitors by TPO reached a plateau at concentrations of less than 100 ng/mL. There was no synergy between TPO and FL, because the addition of FL to TPO did not enhance the survival of total CFU. This observation is in agreement with the study of colony formation in methylcellulose culture (Table 1). In contrast, the combination of IL-6 and FL significantly expanded the total population of CFU.

Table 2.

Survival of Total Cells and Progenitors in Suspension Culture

Cytokines in Primary Culture Cells Total CFU CFU-GEMM CFU-Meg
No culture* 1,000  450  145 50  
Medium  0  0  0  0  
TPO  
   100 ng/mL 356  203  68  15  
 1,000 ng/mL  400  220  53 13  
FL  
   100 ng/mL  222  0  0  0  
 1,000 ng/mL  200  0  0  0  
IL-6  
   100 ng/mL  200 6  1  1  
 1,000 ng/mL  178  5  1  1  
TPO, FL  567  256  50  14  
IL-6, FL  4,267  2,048 171  11 
Cytokines in Primary Culture Cells Total CFU CFU-GEMM CFU-Meg
No culture* 1,000  450  145 50  
Medium  0  0  0  0  
TPO  
   100 ng/mL 356  203  68  15  
 1,000 ng/mL  400  220  53 13  
FL  
   100 ng/mL  222  0  0  0  
 1,000 ng/mL  200  0  0  0  
IL-6  
   100 ng/mL  200 6  1  1  
 1,000 ng/mL  178  5  1  1  
TPO, FL  567  256  50  14  
IL-6, FL  4,267  2,048 171  11 

One thousand LinSca-1+c-kit+ cells were cultured in the presence of designated cytokines. On day 7 of culture, cells were analyzed for total CFU, CFU-GEMM, and CFU-Meg in methylcellulose culture in the presence of SF, IL-3, IL-6, FL, TPO, and EPO.

*

Freshly sorted 1,000 LinSca-1+c-kit+ cells.

Effects of cytokines on the maintenance of long-term repopulating cells.

We then tested the in vivo reconstituting ability of the cultured cells. Based on the observations presented in Tables 1 and 2, the experiment was performed with 100 ng/mL TPO, 100 ng/mL FL, and 100 ng/mL IL-6. As also described in Table 2, the suspension cultures were initiated with 1,000 LinSca-1+c-kit+ C57Bl/6-Ly-5.1 cells in a final volume of 1 mL. After 7 days of incubation, cells in each well were harvested and 1/5 aliquots were injected individually into 5 lethally irradiated Ly-5.2 recipients. As a control group, we transplanted 200 freshly prepared LinSca-1+c-kit+ C57Bl/6-Ly-5.1 cells. The results of analyses of peripheral blood nucleated cells are presented in Fig 1. The numbers of cells transplanted per animal are also presented. Again, the cell population expanded only in the group containing IL-6 and FL. Transplantation of 200 fresh enriched cells resulted in engraftment in 10 of 10 mice, at the levels of 46.4% ± 16.2% and 49.1% ± 24.7% donor cells at 2 and 5 months posttransplantation, respectively. As single agents, both FL and IL-6 failed to support the survival of stem cells. In contrast, the recipients of the cells incubated with TPO alone showed donor cell engraftment in 8 of 8 mice at 2 months (19.7% ± 17.1%) and in 7 of 8 mice at 5 months (24.2% ± 29.8%) posttransplantation. Similar to the result of maintenance of colony-forming cells, the addition of FL to TPO had no benefit. Recipients of the cells cultured with IL-6 and FL showed engraftment levels of 34.3% ± 21.7% and 32.8% ± 25.3% in the peripheral blood at 2 and 5 months posttransplantation, respectively. These data indicated that TPO alone has an ability to maintain the stem cells in culture and that IL-6 acts synergistically with FL to promote the maintenance of LTRC.

Fig. 1.

Long-term repopulating ability of freshly sorted bone marrow cells and cultured cells. (○) Two months posttransplantation. (•) Five months posttransplantation. Results from individual animals are linked by lines. The numbers in parentheses indicate the actual number of cells transplanted per recipient.

Fig. 1.

Long-term repopulating ability of freshly sorted bone marrow cells and cultured cells. (○) Two months posttransplantation. (•) Five months posttransplantation. Results from individual animals are linked by lines. The numbers in parentheses indicate the actual number of cells transplanted per recipient.

Close modal

At 5 months posttransplantation, the proportions of donor blood nucleated cells in each of the T-cell, B-cell, and myeloid (granulocyte and monocyte/macrophage) compartments were determined. As shown in Table 3, T and B lymphocytes and myeloid cells were detected in the peripheral blood of all engrafted recipients and the myeloid/lymphoid ratios did not differ between groups. An example of the analysis of a mouse transplanted with the cells that were cultured with TPO alone is shown in Fig 2.

Table 3.

Lineage Expression by Engrafted Donor (Ly-5.1) Cells in Individual Mice at 5 Months Posttransplantation

Cytokines Mice % B220+ Cells % Thy-1.2+ Cells % Gr-1+, Mac-1+ Cells % Total Myeloid/Lymphoid Ratio
No culture  1  4.8  3.1  2.6  10.5  0.33 
 2  35.5  22.7  14.7  72.9  0.25  
 33.5  20.5  19.6  73.6  0.36  
 4  33.4 21.2  13.5  68.1  0.25  
 5  8.4  6.2  2.4 17.0  0.16  
 6  24.9  18.5  19.9  63.3 0.46  
 7  20.0  17.5  6.5  44.0  0.17 
 8  23.3  22.8  8.6  54.7  0.19  
 10.0  8.5  1.2  19.7  0.06  
 10  32.7  27.3 7.5  67.5  0.13  
 Mean ± SD    49.1 ± 24.7  0.24 ± 0.12* 
TPO  1.9  1.4  1.1  4.4  0.33  
 2  35.9  26.7 22.6  85.2  0.36  
 3  1.7  1.5  1.2  4.4 0.38  
 4  13.8  9.0  5.6  28.4  0.25  
 3.5  2.4  1.5  7.4  0.25  
 6  5.8  3.9 2.2  11.9  0.23  
 7    0.9 
 8  22.7  17.6  10.4  50.7  0.26 
 Mean ± SD    24.2 ± 29.8  0.29 ± 0.06* 
TPO, FL  0.9  0.6  0.8  2.3  0.53  
 2  0.9  0.6 0.7  2.2  0.47  
 3  27.5  25.5  5.0  58.0 0.09  
 4  1.4  1.1  1.1  3.6  0.44  
 20.4  20.4  12.1  36.5  0.30  
 6  32.5 19.8  15.2  67.5  0.29  
 7    0.9  
 8  3.8  2.4  1.4  7.6  0.23 
 9  2.9  1.4  1.3  5.6  0.30 
 Mean ± SD    20.4 ± 26.4  0.33 ± 0.14* 
IL-6, FL  19.2  8.6  6.5  34.3  0.23  
 2  17.9  12.4 8.5  38.8  0.28  
 3  37.3  32.2  22.7  92.2 0.33  
 4  6.4  3.0  3.3  12.7  0.35  
 18.0  8.6  7.9  34.5  0.30  
 6  17.4  10.1 3.9  31.4  0.14  
 7  7.3  4.7  1.3  13.3 0.11  
 8  3.2  1.0  1.1  5.3  0.26  
 15.5  14.9  2.5  32.9  0.08 
 Mean ± SD    32.8 ± 25.3  0.23 ± 0.10* 
Cytokines Mice % B220+ Cells % Thy-1.2+ Cells % Gr-1+, Mac-1+ Cells % Total Myeloid/Lymphoid Ratio
No culture  1  4.8  3.1  2.6  10.5  0.33 
 2  35.5  22.7  14.7  72.9  0.25  
 33.5  20.5  19.6  73.6  0.36  
 4  33.4 21.2  13.5  68.1  0.25  
 5  8.4  6.2  2.4 17.0  0.16  
 6  24.9  18.5  19.9  63.3 0.46  
 7  20.0  17.5  6.5  44.0  0.17 
 8  23.3  22.8  8.6  54.7  0.19  
 10.0  8.5  1.2  19.7  0.06  
 10  32.7  27.3 7.5  67.5  0.13  
 Mean ± SD    49.1 ± 24.7  0.24 ± 0.12* 
TPO  1.9  1.4  1.1  4.4  0.33  
 2  35.9  26.7 22.6  85.2  0.36  
 3  1.7  1.5  1.2  4.4 0.38  
 4  13.8  9.0  5.6  28.4  0.25  
 3.5  2.4  1.5  7.4  0.25  
 6  5.8  3.9 2.2  11.9  0.23  
 7    0.9 
 8  22.7  17.6  10.4  50.7  0.26 
 Mean ± SD    24.2 ± 29.8  0.29 ± 0.06* 
TPO, FL  0.9  0.6  0.8  2.3  0.53  
 2  0.9  0.6 0.7  2.2  0.47  
 3  27.5  25.5  5.0  58.0 0.09  
 4  1.4  1.1  1.1  3.6  0.44  
 20.4  20.4  12.1  36.5  0.30  
 6  32.5 19.8  15.2  67.5  0.29  
 7    0.9  
 8  3.8  2.4  1.4  7.6  0.23 
 9  2.9  1.4  1.3  5.6  0.30 
 Mean ± SD    20.4 ± 26.4  0.33 ± 0.14* 
IL-6, FL  19.2  8.6  6.5  34.3  0.23  
 2  17.9  12.4 8.5  38.8  0.28  
 3  37.3  32.2  22.7  92.2 0.33  
 4  6.4  3.0  3.3  12.7  0.35  
 18.0  8.6  7.9  34.5  0.30  
 6  17.4  10.1 3.9  31.4  0.14  
 7  7.3  4.7  1.3  13.3 0.11  
 8  3.2  1.0  1.1  5.3  0.26  
 15.5  14.9  2.5  32.9  0.08 
 Mean ± SD    32.8 ± 25.3  0.23 ± 0.10* 

Lineage expression of the engrafted donor cells was analyzed at 5 months posttransplantation. Background (peripheral blood of nontransplanted male mice) staining by anti–Ly-5.1 MoAb (A20-1.7) was less than 1.0%. Because the donor cells in the recipient mice that had been transplanted with cells cultured with FL or IL-6 alone showed less than 1.0%, analysis of lineage phenotypes was not performed.

*

There were no significant differences of the myeloid (Gr-1+, Mac-1+ cells)/lymphoid (B220+ cells and Thy-1.2+ cells) ratios among the experimental groups by unpaired t-test.

Because no donor cells were detected in these animals, analysis of lineage phenotypes was not performed.

Fig. 2.

Hematopoietic reconstitution by cells cultured with TPO alone. Nucleated cells of peripheral blood were analyzed by flow cytometry 5 months after transplantation. Thy-1.2+ cells, B220+ cells, and Gr-1+Mac-1+cells of donor (Ly-5.1) origin are seen. The analyses of additional samples are presented in Table 4.

Fig. 2.

Hematopoietic reconstitution by cells cultured with TPO alone. Nucleated cells of peripheral blood were analyzed by flow cytometry 5 months after transplantation. Thy-1.2+ cells, B220+ cells, and Gr-1+Mac-1+cells of donor (Ly-5.1) origin are seen. The analyses of additional samples are presented in Table 4.

Close modal
Mechanisms of LTRC maintenance.

Earlier, we reported that primitive murine progenitors in G0 are stimulated to proliferate in culture by a combination of IL-6 and FL.15 Therefore, the maintenance of LTRC in culture by the combination in of IL-6 and FL may be the result of active cell division and self-renewal of stem cells rather than the survival of LTRC in dormancy. To test this hypothesis, we performed a reconstitution experiment by using PKH26. This dye has been used previously to study division history of hematopoietic cells in culture,61-64 because its intensity is reduced by roughly one half with each cell division. Dot plots of the cells stained with PKH26 dye before (A) and after suspension culture (B and C) are presented in Fig 3. We made an arbitrary separation of PKH26high from PKH26lowpopulations as shown in Fig 3. Before culture, all cells were PKH26high. After 7 days of culture, the majority of the cells became PKH26low. The four cell populations defined in Fig 3 (BI, BII, CI, and CII) were prepared by sorting, and their in vivo reconstituting abilities were tested by transplantation into lethally irradiated Ly-5.2 mice together with 4 × 105compromised marrow cells of female C57Bl/6-Ly-5.2 mice. One fourth aliquots of the sorted PKH26low cells (2,720 cells) or 1/4 aliquots of the PKH26high cells (250 cells) cultured with TPO were injected individually into each of 4 recipients. One fifth aliquots of the sorted PKH26low cells (36,415 cells) or 1/5 aliquots of PKH26high cells (1,055 cells) cultured with IL-6 and FL were injected individually into each of 5 recipients. Of the cells cultured under either conditions, PKH26highpopulations showed greater reconstitution activity than that of PKH26low populations (Fig 4). In the IL-6 plus FL group, PKH26low cells exhibited some reconstituting capability. There may have been a limited amount of self-renewal. The proportions of donor blood nucleated cells in each of T-cell, B-cell, and myeloid (granulocyte and monocyte/macrophage) compartments were determined. T and B lymphocytes and myeloid cells were detected in the peripheral blood of all engrafted recipients (Table 4). These data indicated that TPO alone and combination of IL-6 and FL can support the survival of stem cells without stimulating their active cell proliferation.

Fig. 3.

Flow cytometric analysis and sorting windows of cells tracked with PKH26. (A) PKH26 fluorescence of freshly sorted LinSca-1+c-kit+ cells stained with PKH26 on day 0. (B and C) PKH26 fluorescence of the cell populations after 7 days of suspension culture with TPO (B) or IL-6 and FL (C). Viable (PI-negative) cells were arbitarily divided into PKH26low populations (I) and PKH26highpopulations (II): BI, 89%; BII, 8%; CI, 94%; and CII, 2.7%.

Fig. 3.

Flow cytometric analysis and sorting windows of cells tracked with PKH26. (A) PKH26 fluorescence of freshly sorted LinSca-1+c-kit+ cells stained with PKH26 on day 0. (B and C) PKH26 fluorescence of the cell populations after 7 days of suspension culture with TPO (B) or IL-6 and FL (C). Viable (PI-negative) cells were arbitarily divided into PKH26low populations (I) and PKH26highpopulations (II): BI, 89%; BII, 8%; CI, 94%; and CII, 2.7%.

Close modal
Fig. 4.

Hematopoietic reconstitution by PKH26 stained cells. The four cell populations in Fig 3 (BI, BII, CI, and CII) were prepared by sorting and their in vivo reconstituting abilities were analyzed at 5 months posttransplantation.

Fig. 4.

Hematopoietic reconstitution by PKH26 stained cells. The four cell populations in Fig 3 (BI, BII, CI, and CII) were prepared by sorting and their in vivo reconstituting abilities were analyzed at 5 months posttransplantation.

Close modal
Table 4.

Lineage Expression by PKH26-Tracked Donor (Ly-5.1) Cells in Individual Mice

Cytokines PKH26 Staining (total cells) Mice % B220+ Cells % Thy-1.2+ Cells % Gr-1+ Mac-1+ Cells % TotalMyeloid/Lymphoid Ratio
TPO  High (3.5 × 104)  1  9.1  8.6  4.8  22.5 0.27  
  2  17.5  16.2  5.7  39.4  0.17 
  3  18.8  12.3  6.9  38.0  0.22  
  23.3  21.5  4.7  49.5  0.10 
  Mean ± SD    37.4 ± 11.1  0.19 ± 0.073-150 
 Low (3.1 × 103)  1     0.9  
     0.3  
  3     0.2  
     0.1  
  Mean ± SD    0.4 ± 0.4  
IL-6, FL  High (4.0 × 105)  1  35.1  18.9  19.1  73.1 0.35  
  2  8.5  22.7  4.9  36.1  0.16 
  3  37.3  26.2  16.0  79.5  0.25 
  4  30.3  13.4  32.3  76.0  0.74 
  5  23.4  20.6  24.1  68.1  0.55 
  Mean ± SD    66.6 ± 17.5  0.41 ± 0.233-150 
 Low (1.2 × 104)  1  6.5  2.3  1.4  10.2 0.16  
  2  2.2  2.2  1.7  6.1  0.39 
  3  2.4  1.2  1.1  4.7  0.31  
  2.0  1.6  1.3  4.9  0.36  
  5  8.2  1.1 1.1  10.4  0.12 
  Mean ± SD    7.3 ± 2.8  0.27 ± 0.123-150 
Cytokines PKH26 Staining (total cells) Mice % B220+ Cells % Thy-1.2+ Cells % Gr-1+ Mac-1+ Cells % TotalMyeloid/Lymphoid Ratio
TPO  High (3.5 × 104)  1  9.1  8.6  4.8  22.5 0.27  
  2  17.5  16.2  5.7  39.4  0.17 
  3  18.8  12.3  6.9  38.0  0.22  
  23.3  21.5  4.7  49.5  0.10 
  Mean ± SD    37.4 ± 11.1  0.19 ± 0.073-150 
 Low (3.1 × 103)  1     0.9  
     0.3  
  3     0.2  
     0.1  
  Mean ± SD    0.4 ± 0.4  
IL-6, FL  High (4.0 × 105)  1  35.1  18.9  19.1  73.1 0.35  
  2  8.5  22.7  4.9  36.1  0.16 
  3  37.3  26.2  16.0  79.5  0.25 
  4  30.3  13.4  32.3  76.0  0.74 
  5  23.4  20.6  24.1  68.1  0.55 
  Mean ± SD    66.6 ± 17.5  0.41 ± 0.233-150 
 Low (1.2 × 104)  1  6.5  2.3  1.4  10.2 0.16  
  2  2.2  2.2  1.7  6.1  0.39 
  3  2.4  1.2  1.1  4.7  0.31  
  2.0  1.6  1.3  4.9  0.36  
  5  8.2  1.1 1.1  10.4  0.12 
  Mean ± SD    7.3 ± 2.8  0.27 ± 0.123-150 

LinSca-1+c-kit+ cells (1 × 105) were stained with PKH26 on day 0 and incubated in suspension culture with TPO or with IL-6 and FL for 7 days. PKH26low and PKH26high cells were prepared by sorting and their reconstitution abilities tested. One fourth aliquots of PKH26low (2,720 cells) and PKH26high cells (250 cells) cultured with TPO were injected into each of 4 recipients. One-fifth aliquots of PKH26low(36,415 cells) and PKH26high cells (1,055 cells) cultured with IL-6 and FL were injected into each of 5 recipients. Lineage expression of the engrafted donor cells was analyzed at 5 months posttransplantation. Background (peripheral blood of nontransplanted female mice) staining by anti–Ly-5.1 MoAb (A20-1.7) was less than 1.0%.

F3-150

There were no significant differences of the myeloid (Gr-1+, Mac-1+ cells)/lymphoid (B220+ cells and Thy-1.2+ cells) ratios among the experimental groups by unpaired t-test.

In this study, we have examined the effects of TPO, FL, and IL-6 on the survival of murine LTRC. We used LinSca-1+c-kit+ marrow cells that had been prepared from 5-FU–treated mice. This cell population represents 0.04% of the unfractionated marrow cells and has been shown to be capable of hematopoietic reconstitution in lethally irradiated mice.28,65 As a single agent, TPO was the best for supporting the maintenance of colony-forming cells and survival of LTRC in 7-day suspension culture. Earlier, Kaushansky et al32,66had reported that TPO alone can support the survival without proliferation of a fraction of mouse Hoescht 33342lowRhodamine123low cells that are highly enriched for LTRC. Together, those results are consistent with the recent observations that megakaryocyte, erythroid, and myeloid progenitors are reduced in TPO-deficient mice.53 54 TPO appears to be an important cytokine in the physiological regulation of hematopoietic stem cells.

FL as a single agent failed to maintain the viability of colony-forming cells or LTRC. Muench et al27 described that FL can support the survival of human fetal liver colony-forming cells in suspension culture for 7 days. Human fetal liver cell progenitors may respond to FL differently from adult murine marrow progenitors. Veiby et al22 reported that FL alone can support the survival of murine bone marrow colony-forming cells in suspension culture for 40 hours. This incubation period was much shorter than ours. As summarized in a recent review, a number of investigators have shown synergy between FL and early-acting cytokines, such as IL-6, IL-11, and G-CSF, on primitive hematopoietic progenitors.67 In this report, we demonstrated that FL and IL-6 synergize to support in vitro survival of stem cells. These observations are consistent with the report from Mackarehtschian et al68 that bone marrow cells of FLT3/FLK-2–deficient mice have impaired competitive long-term repopulating ability.

We reported previously that TPO and IL-6 belong to the same group of cytokines that trigger the dormant hematopoietic progenitors into cell cycle.6,30 Because of their functional similarity, we compared their effects on the survival of colony-forming cells and LTRC. In contrast to TPO, IL-6 alone could not support the survival of LTRC, which is in agreement with the report by Li and Johnson.24 Although IL-6 and FL showed little effects as single agents, they acted synergistically to promote the survival of LTRC. Earlier, McKinstry et al69 reported that the IL-6 receptor is expressed by the cell population highly enriched for LTRC. These observations are consistent with the report from Bernad et al70 that absolute numbers of CFU-Sd12, pre-CFU-S and LTRC are decreased in IL-6–deficient mice.

PKH26high populations cultured with either TPO alone or the combination of IL-6 and FL were more efficient in their bone marrow reconstitution activity than PKH26low populations. Traycoff et al64 documented similar results by using cells cultured with SF, IL-1α, IL-3, and IL-6. These results suggest that the ability of cultured cells to contribute to long-term reconstitution may be derived primarily from quiescent cells and not from de novo-generated progeny stem cells.

The authors thank Dr Haiqun Zeng for assistance in cell sorting, Dr Pamela N. Pharr and Anne G. Livingston in preparation of this manuscript, and the staff of the Radiation Oncology Department of the Medical University of South Carolina for irradiation of mice.

Supported by National Institutes of Health Grants No. RO1 DK32294 and RO1 DK48714 and by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs.

Address reprint requests to Makio Ogawa, MD, PhD, Ralph H. Johnson Medical Center, 109 Bee St, Charleston, SC 29401-5799.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" is accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1998 by the American Society of Hematology.

1
Ogawa
M
Differentiation and proliferation of hematopoietic stem cells.
Blood
81
1993
2844
2
Suda
T
Suda
J
Ogawa
M
Ihle
JN
Permissive role of interleukin 3 (IL-3) in proliferation and differentiation of multipotential hemopoietic progenitors in culture.
J Cell Physiol
124
1985
182
3
Kishi
K
Ihle
JN
Urdal
DL
Ogawa
M
Murine B-cell stimulatory factor-1 (BSF-1)/interleukin-4 (IL-4) is a multilineage colony-stimulating factor that acts directly on primitive hemopoietic progenitors.
J Cell Physiol
139
1989
463
4
Koike
K
Ogawa
M
Ihle
JN
Miyake
T
Shimizu
T
Miyajima
A
Yokota
T
Arai
K
Recombinant murine granulocyte-macrophage (GM) colony-stimulating factor supports formation of GM and multipotential blast cell colonies in culture: Comparison with the effects of interleukin-3.
J Cell Physiol
131
1987
458
5
Metcalf
D
The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors.
Blood
67
1986
257
6
Ikebuchi
K
Wong
GG
Clark
SC
Ihle
JN
Hirai
Y
Ogawa
M
Interleukin 6 enhanced of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.
Proc Natl Acad Sci USA
84
1987
9035
7
Musashi
M
Clark
SC
Sudo
T
Urdal
DL
Ogawa
M
Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice.
Blood
78
1991
1448
8
Musashi
M
Yang
YC
Paul
SR
Clark
SC
Sudo
T
Ogawa
M
Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture.
Proc Natl Acad Sci USA
88
1991
765
9
Hirayama
F
Katayama
N
Neben
S
Donaldson
D
Nickbarg
EB
Clark
SC
Ogawa
M
Synergistic interaction between interleukin-12 and steel factor in support of proliferation of murine lymphohematopoietic progenitors in culture.
Blood
83
1994
92
10
Ikebuchi
K
Clark
SC
Ihle
JN
Souza
LM
Ogawa
M
Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.
Proc Natl Acad Sci USA
85
1988
3445
11
Leary
AG
Wong
GG
Clark
SC
Smith
AG
Ogawa
M
Leukemia inhibitory factor differentiaton-inhibiting activity/human interleukin for DA cells augments proliferation of human hematopoietic stem cells.
Blood
75
1990
1960
12
Leary
AG
Zeng
HQ
Clark
SC
Ogawa
M
Growth factor requirements for survival in Go and entry into the cell cycle of primitive human hemopoietic progenitors.
Proc Natl Acad Sci USA
89
1992
4013
13
Tsuji
K
Zsebo
KM
Ogawa
M
Enhancement of murine blast cell colony formation in culture by recombinant rat stem cell factor, ligand for c-kit.
Blood
78
1991
1223
14
Tsuji
K
Lyman
SD
Sudo
T
Clark
SC
Ogawa
M
Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture.
Blood
79
1992
2855
15
Hirayama
F
Lyman
SD
Clark
SC
Ogawa
M
The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors.
Blood
85
1995
1762
16
Williams
DE
Broxmeyer
HE
Interleukin-1 a enhances the in vitro survival of purified murine granulocyte-macrophage progenitor cells in the absence of colony stimulating factors.
Blood
72
1988
1608
17
Bodine
DM
Karlsson
S
Nienhuis
AW
Combination of interleukin 3 and 6 preserves stem cell function in culture and enhances retrovirus mediated gene transfer into hematopoietic stem cells.
Proc Natl Acad Sci USA
86
1989
8897
18
Bodine
DM
Crosier
PS
Clark
SC
Effects of hematopoietic growth factors on the survival of primitive stem cells in liquid suspension culture.
Blood
78
1991
914
19
Bodine
DM
Orlic
D
Birkett
NC
Seidel
NE
Zsebo
KM
Stem cell factor increases colony forming unit-spleen number in vitro in synergy with interleukin-6, and in vivo in Sl/Sld mice as a single factor.
Blood
79
1992
913
20
Katayama
N
Clark
SC
Ogawa
M
Growth factor requirement for survival in cell-cycle dormancy of primitive murine lymphohematopoietic progenitors.
Blood
81
1993
610
21
de Vries
P
Brasel
KA
Eisenman
JR
Alpert
AR
Williams
DE
The effect of recombinant mast cell growth factor on purified murine hematopoietic stem cells.
J Exp Med
173
1991
1205
22
Veiby
OP
Jacobsen
FW
Cui
L
Lyman
SD
Jacobsen
EW
The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential.
J Immunol
157
1996
2953
23
Miura
N
Okada
S
Zsebo
KM
Miura
Y
Suda
T
Rat stem cell factor and IL-6 preferentially support the proliferation of c-kit-positive murine hemopoietic cells rather than their differentiation.
Exp Hematol
21
1993
143
24
Li
CL
Johnson
GR
Stem cell factor enhances the survival but not the self-renewal of murine hematopoietic long-term repopulating cells.
Blood
84
1994
408
25
Keller
JR
Oritz
M
Ruscetti
FW
Steel factor (c-kit ligand) promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division.
Blood
86
1995
1757
26
Brandt
JE
Bhalla
K
Hoffman
R
Effects of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells.
Blood
83
1994
1507
27
Muench
MO
Roncarolo
MG
Menon
S
Xu
Y
Kastelein
R
Zurawski
S
Hannum
CH
Culpepper
J
Lee
F
Namikawa
R
FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver.
Blood
85
1995
963
28
Yonemura
Y
Ku
H
Lyman
SD
Ogawa
M
In vitro expansion of hematopoietic progenitors and maintenance of stem cells: Comparison between FLT3/FLK-2 ligand and KIT ligand.
Blood
89
1997
1915
29
Petzer
AL
Zandstra
PW
Piret
JM
Eaves
CJ
Differential cytokine effects on primitive (CD34+CD38−) human hematopoietic cells: Novel responses to flt3-ligand and thrombopoietin.
J Exp Med
183
1996
2551
30
Ku
H
Yonemura
Y
Kaushansky
K
Ogawa
M
Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.
Blood
87
1996
4544
31
Kobayashi
M
Laver
JH
Kato
T
Miyazaki
H
Ogawa
M
Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3.
Blood
88
1996
429
32
Sitnicka
E
Lin
N
Priestley
GV
Fox
N
Broudy
VC
Wolf
NS
Kaushansky
K
The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.
Blood
87
1996
4998
33
de Sauvage
FJ
Hass
PE
Spencer
SD
Malloy
BE
Gurney
AL
Spencer
SA
Darbonne
WC
Henzel
WJ
Wong
SC
Kuang
WJ
Oles
KJ
Hultgren
B
Solberg LA Jr
Goeddel
DV
Eaton
DL
Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.
Nature
369
1994
533
34
Lok
S
Kaushansky
K
Holly
RD
Kuijper
JL
Lofton-Day
CE
Oort
PJ
Grant
FJ
Heipel
MD
Burkhead
SK
Kramer
JM
Bell
LA
Sprecher
CA
Blumberg
H
Johnson
R
Prunkard
D
Ching
AFT
Mathews
SL
Bailey
MC
Forstrom
JW
Buddle
MM
Osborn
SG
Evans
SJ
Sheppard
PO
Presnell SR
O
Hara
PJ
Hagen
FS
Roth
GJ
Foster
DC
Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo.
Nature
369
1994
565
35
Kaushansky
K
Lok
S
Holly
RD
Broudly
VC
Lin
N
Bailey
MC
Forstrom
JW
Buddle
MM
Oort
PJ
Hagen
FS
Roth
GJ
Papayannopoulou
T
Foster
DC
Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin.
Nature
369
1994
568
36
Wendling
F
Maraskovsky
E
Debili
N
Florindo
C
Teepe
M
Titeux
M
Methia
N
Breton-Gorius
J
Cosman
D
Vainchenker
W
c-Mpl ligand is a humoral regulator of megakaryocytopoiesis.
Nature
369
1994
571
37
Bartley
TD
Bogenberger
J
Hunt
P
Li
Y-S
Lu
HS
Martin
F
Chang
M-S
Samal
B
Nichol
JL
Swift
S
Johnson
MJ
Hsu
R-Y
Parker
VP
Suggs
S
Skrine
JD
Merewether
LA
Clogston
C
Hsu
E
McNinch
J
Simonet
L
Jacobsen
J
Xie
C
Shutter
J
Chute
H
Basu
R
Selander
L
Trollinger
D
Sieu
L
Padilla
D
Trail
G
Elliott
G
Izumi
R
Covey
T
Crouse
J
Garcia
A
Xu
W
Del Castillo
J
Biron
J
Cole
S
Hu
MC-T
Pacifici
R
Ponting
I
Saris
C
Wen
D
Yung
YP
Lin
H
Bosselman
RA
Identification and cloning of megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.
Cell
77
1994
1117
38
Sohma
Y
Akahori
H
Seki
N
Hori
T
Ogami
K
Kato
T
Shimada
Y
Kawamura
K
Miyazaki
H
Molecular cloning and chromosomal localization of the human thrombopoietin gene.
FEBS Lett
353
1994
57
39
Kato
T
Ogami
K
Shimada
Y
Iwamatsu
A
Sohma
Y
Akahori
H
Horie
K
Kokubo
A
Kudo
Y
Maeda
E
Kobayashi
K
Ohashi
H
Ozawa
T
Inoue
H
Kawamura
K
Miyazaki
H
Purification and characterization of thrombopoietin.
J Biochem
118
1995
229
40
Kuter
DJ
Beeler
DL
Rosenberg
RD
The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production.
Proc Natl Acad Sci USA
91
1994
11104
41
Zeigler
FC
de Sauvage
F
Widmer
HR
Keller
GA
Donahue
C
Schreiber
RD
Malloy
B
Hass
P
Eaton
D
Matthews
W
In vitro megakaryopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells.
Blood
84
1994
4045
42
Kaushansky
K
Thrombopoietin: The primary regulator of platelet production.
Blood
86
1995
419
43
Broudy
VC
Lin
NL
Kaushansky
K
Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro.
Blood
85
1995
1719
44
Gurney
AL
Carver-Moore
K
de Sauvage
FJ
Moore
MW
Thrombocytopenia in c-mpl-deficient mice.
Science
265
1994
1445
45
Souyri
M
Vigon
I
Pencioelli
J-F
Heard
J-M
Tambourin
P
Wendling
F
A putative truncated cytokine receptor gene transduced by myeloproliferative leukemia virus immortalizes hematopoietic progenitors.
Cell
63
1990
1137
46
Vigon
I
Mornon
J-P
Cocault
L
Mitjavila
M-T
Tambourin
P
Gisselbrecht
S
Souyri
M
Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor superfamily.
Proc Natl Acad Sci USA
89
1992
5640
47
Methia
N
Louache
F
Vainchenker
W
Wendling
F
Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis.
Blood
82
1993
1395
48
Alexander
WS
Dunn
AR
Structure and transcription of the genomic locus encoding murine c-Mpl, a receptor for thrombopoietin.
Oncogene
10
1995
795
49
Berardi
AC
Wang
A
Levine
JD
Lopez
P
Scadden
DT
Functional isolation and characterization of human hematopoietic stem cells.
Science
267
1995
104
50
Fibbe
W
Heemskerk
D
Laterveer
L
Pruijt
J
Foster
D
Kaushansky
K
Willemze
R
Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice.
Blood
86
1995
3308
51
Kaushansky
K
Broudy
VC
Grossman
A
Humes
J
Lin
N
Ren
HP
Bailey
MC
Papayannopoulou
T
Forstrom
JW
Sprugel
KH
Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy.
J Clin Invest
96
1995
1683
52
Grossman
A
Lenox
J
Deisher
TA
Ren
HP
Humes
JM
Kaushansky
K
Sprugel
KH
Synergistic effects of thrombopoietin and granulocyte colony-stimulating factor on neutrophil recovery in myelosuppressed mice.
Blood
88
1996
3363
53
Alexander
WS
Roberts
AW
Nicola
NA
Li
R
Metcalf
D
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl.
Blood
87
1996
2162
54
Carver-Moore
K
Broxmeyer
HE
Luoh
SM
Cooper
S
Peng
J
Burstein
SA
Moore
MW
de Sauvage
FJ
Low level of erythroid and myeloid progenitors in thrombopoietin and c-mpl-deficient mice.
Blood
88
1996
803
55
Lyman
SD
James
L
Vanden Bos
T
de Vries
P
Brasel
K
Gliniak
B
Hollingworth
LT
Picha
KS
McKenna
HJ
Splett
RR
Fletcher
FF
Maraskovsky
E
Farrah
T
Foxworthe
D
William
DE
Beckmann
MP
Molecular cloning of a ligand for the flt3/flk2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells.
Cell
75
1993
1157
56
Shih
JP
Zeng
HQ
Ogawa
M
Enrichment of murine marrow cells for progenitors of multilineage hematopoietic colonies.
Leukemia
6
1992
193
57
Ortega
G
Korty
PE
Shevach
EM
Malek
TR
Role of Ly-6 in lymphocyte activation. I. Characterization of a monoclonal antibody to a nonpolymorphic Ly-6 specificity.
J Immunol
137
1986
3240
58
Nishikawa
S
Kusakabe
M
Yoshinaga
K
Ogawa
M
Hayashi
S
Kunisada
T
Nishikawa
S-I
In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: Two distinct waves of c-kit-dependency during melanocyte development.
EMBO J
10
1991
2111
59
Nakahata
T
Ogawa
M
Clonal origin of murine hemopoietic colonies with apparent restriction to granulocyte-macrophage-megakaryocyte (GMM) differentiation.
J Cell Physiol
111
1982
239
60
Harrison
DE
Astle
CM
Delaittre
JA
Loss of proliferative capacity in immunohemopoietic stem cells caused by serial transplantation rather than aging.
J Exp Med
147
1987
1526
61
Lansdorp
PM
Dragowska
W
Maintenance of hematopoiesis in serum-free bone marrow cultures involves sequential recruitment of quescent progenitors.
Exp Hematol
21
1993
1321
62
Lansdorp
M
Dragowska
W
Mayani
H
Ontogeny-related changes in proliferative potential of human hematopoietic cells.
J Exp Med
178
1993
787
63
Young
JC
Varma
A
DiGiusto
D
Backer
MP
Retention of quiescent hematopoietic cells with high proliferative potential during ex vivo stem cell culture.
Blood
87
1996
545
64
Traycoff
CM
Cornetta
K
Yoder
MC
Davidson
A
Srour
EF
Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential.
Exp Hematol
24
1996
299
65
Yonemura
Y
Ku
H
Hirayama
F
Souza
LM
Ogawa
M
Interleukin-3 or interleukin-1 abrogates the reconstitution ability of hematopoietic stem cells.
Proc Natl Acad Sci USA
93
1996
4040
66
(suppl 1)
Kaushansky
K
Thrombopoietin: More than a lineage-specific megakaryocyte growth factor.
Stem Cells
15
1997
97
67
Lyman
SD
Jacobsen
SEW
c-kit ligand and flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities.
Blood
91
1998
1101
68
Mackarehschian
K
Hardin
JD
Moore
KA
Boast
S
Goff
SP
Lemischka
IR
Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.
Immunity
3
1995
147
69
McKinstry
WJ
Li
C-L
Rasko
JEJ
Nicola
NA
Johnson
GR
Metcalf
D
Cytokine receptor expression on hematopoietic stem and progenitor cells.
Blood
89
1997
65
70
Bernad
A
Kopf
M
Kulbacki
R
Weich
N
Koehler
G
Gutierrez-Ramos
JC
Interleukin-6 is required in vivo for the regulation of stem cells and comitted progenitors of the hematopoietic system.
Immunity
1
1994
725
Sign in via your Institution